Associate Professor, Chief of Genitourinary Medical Oncology, Miami Cancer Institute, Baptist Health
Miami, FL
Joined November 2020
- Tweets450
- Following407
- Followers653
- Likes1.7K
Rohan Garje, MD, FASCO retweeted
Just in๐today @US_FDA approved Pluvicto (Lutetium-177)for PSMA+ metastatic androgen pathway modulation-sensitive #prostatecancer (mAPMS/mHSPC), based on the results of ph3 PSMAddition trial๐ @PCF_Science @urotoday @OncoAlert Congrats @DrScottTagawa & team
Rohan Garje, MD, FASCO retweeted
Great conversations always with my dear friend @BrainTumorDoc on science at #ASCO26 @ASCO and much more. @BaptistHealthSF is thriving under your leadership.
Rohan Garje, MD, FASCO retweeted
New data from @ASTRO_org #MRPTS26 presented by @Ganiyani_MD & @RohanGarjeMD reinforce the promise of 177Lu-PSMA-617 in advanced prostate cancer, showing a consistent ability to delay disease progression across randomized trials. Learn More ๐
nitter.gq/MiamiCancerInst/statusโฆ
Rohan Garje, MD, FASCO retweeted
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
Rohan Garje, MD, FASCO retweeted
๐ถ Wondering how to tackle variant histologies in bladder cancer?
Think of them as music genresโsame stage, different openers (neoadj.) and headliners (1st line tx).
๐ค From micropapillary to plasmacytoidโeach has a style & strategy.
๐ง Watch here โฌ๏ธ
@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer.
Rohan Garje, MD, FASCO retweeted
@ASCO Guideline Clinical Insights: Systemic therapy in mCRPC, released Sept 4, 2025. Thanks to @rohangarjeMD, Dr. Rahul Parikh, @IrbazRiaz, and Dr. Arsalan Naqvi for their leadership on this article.
Rohan Garje, MD, FASCO retweeted
@ASCO updates #mCRPC guidelines for the first time in 10 years. Emphasis on individualized care, ongoing ADT, & #BiomarkerTesting. Key trials include MAGNITUDE, TALAPRO-2, and PROpel. @RohanGarjeMD: โThis represents a shift toward #PrecisionOncology.โ bit.ly/3FSrJki
Rohan Garje, MD, FASCO retweeted
The Updated ASCO Guidelines on Metastatic Castration-Resistant Prostate Cancer - @RohanGarjeMD
@BryanRumble @ASCO
oncodaily.com/url/289209
#Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #CancerWorld #ASCO #mCRPC
Rohan Garje, MD, FASCO retweeted
๐ฃOut now #ASCOGuidelines Update: Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/full/10.120โฆ #pcsm @ASCO @RohanGarjeMD
Rohan Garje, MD, FASCO retweeted
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
@ASCO Guideline Update
ascopubs.org/doi/full/10.120โฆ
The updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer (mCRPC). Therapeutic options with demonstrated overall survival benefit include androgen receptor pathway inhibitors (ARPIs), ๐PARP inhibitors, chemotherapy (docetaxel, cabazitaxel), radiopharmaceuticals โข๏ธ(radium-223, 177Lu-PSMA-617), and sipuleucel-T. For patients with BRCA1/2 alterations, ARPIโPARP inhibitor combinations or PARP inhibitor monotherapy are recommended based on prior treatments. Continued androgen-deprivation therapy, early somatic genetic testing, ๐ฆดbone-protective agents for patients with bone metastases, and palliative care are advised. Treatment selection should be guided by prior systemic therapies, although optimal sequencing remains unclear.
@RohanGarjeMD @IrbazRiaz @SyedArsalanN @BryanRumble @TiansterZhang @katy_beckermann @NehaVapiwala @sebastienhotte @arnabguonc @AlanBryce9 @lisabodei @DrAndrewLoblaw @HamidEmamekhoo @thomashopemd @M_Hassan_Murad @hongfangliu
Ping
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima
๐จ New @ASCO Guideline on #mCRPC just published!
Glad to co-author recs on sequencing, #PARP inhibitors, #genomics, chemo & radiopharmaceuticals
Grateful to expert panel
@BryanRumble @IrbazRiaz #RahulParikh @AlanBryce9 @JCO_ASCO @OncoAlert @OncLive
๐ascopubs.org/doi/10.1200/JCOโฆ
Rohan Garje, MD, FASCO retweeted
ASCO 2024 mCRPC Update:
๐ Put patients first: tailor to comorbidities, life expectancy & access
๐งฌ Genomic testing (BRCA1/2, HRR, MSI, TMB) = must
๐งฌ PARP inhibitors: for BRCA1/2, maybe others
โข๏ธ Lu-PSMA: for PSMA+ after ARPI & chemo
โ No ARPI after ARPIโunless no options
#ProstateCancer #mCRPC #ASCO24 #Oncology #PrecisionMedicine
@ASCO @JCO_ASCO @APCCC_Lugano @OncoAlert @RohanGarjeMD @IrbazRiaz @TiansterZhang @katy_beckermann @NehaVapiwala @PCFnews @Larvol @OncBrothers
doi.org/10.1200/JCO-25-00007
Rohan Garje, MD, FASCO retweeted
If you can get it (especially in ๐บ๐ธ), can't argue with the cost of BCG: 1 yr, $1800 ๐
#EAU25 debate -- @GGiannarini making the point that BCG is still the best option for HR NMIBC @urotoday
Discussing @EUplatinum paper from Scilipoti, @UroMoschini @UrogerliMD @spsutkaMD @UroDocAsh et al.
Rohan Garje, MD, FASCO retweeted
โญ๏ธDr. Pedro Barata gives a very thoughtful discussion of how to navigate 1st line RCC data in 2025 to provide best care for our patients. LOVE the updated table below. #AtlantaGU25
@binaytara @ZakhariaYousef @bilenma @RohanGarjeMD @BaptistHealthSF
@WinshipAtEmory @binaytara @DocMattCampbell @rohitjainMD @WeillCornell @arnabguonc @ONealCancerUAB @PBarataMD @UHhospitals , @maughanonc @Huntsman_GU @AJangMD @OncLive @OncoAlert @kidneycan @oncodaily
Rohan Garje, MD, FASCO retweeted
#AtlantaGU25 starting with prostate cancer. Chaired by @WinshipAtEmory Dr Brad Carthon. Lots of updates in both the metastatic hormonal sensitive and castrate resistant spaces with @CParkMD and @RohanGarjeMD. @binaytara
Rohan Garje, MD, FASCO retweeted
๐ We kick off #AtlantaGU25 with @CParkMD from @Norton_Health, @RohanGarjeMD from @BaptistHealthSF and Dr. Louis Crain Garrot from Georgia Cancer Specialists discussing #prostatecancer ๐ฌ. Session Chair: Dr. Bradley Carthon from @WinshipAtEmory. ๐ Visit education.binayfoundation.orโฆ for more upcoming CME conferences! #MedTwitter #MedX #MedEd
Rohan Garje, MD, FASCO retweeted
Systemic Therapy Update on
177Lutetium-PSMA-617 for Metastatic
Castration-Resistant Prostate Cancer: ASCO
Guideline Rapid Recommendation Q and A
ascopubs.org/doi/pdf/10.1200โฆ
ASCO released a rapid recommendation update on lutetium-177 (177Lu)-PSMA-617 for treating metastatic castration-resistant #ProstateCancer (mCRPC). This therapy targets PSMA-expressing tumor cells with beta-particle radiation, causing DNA damage and potential cell death.
The update is based on a trial by Sartor et al., which showed improved progression-free survival (8.7 months vs. 3.4 months) and overall survival (15.3 months vs. 11.3 months) in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months. Expert panel members also provide additional insights in a Q&A format.
@RohanGarjeMD
@thomashopemd
@BryanRumble
Ping @OncoAlert ๐จ @nataliagandur @bavilima
Rohan Garje, MD, FASCO retweeted
Excited to co-chair this first GU summit with @bilenma in Atlanta with great lineup of speakers @PBarataMD @CParkMD @RohanGarjeMD @maughanonc @binayshah @arnabguonc @virajmaster @DocMattCampbell @BasselNazha and many more canโt find on X, 15 travel grants offered to trainees.
๐
Join us at the Atlanta Genitourinary Cancers Summit on Mar. 15, co-chaired by Winship medical oncologist Mehmet Asim Bilen, MD, and Mayo Clinic's Yousef Zakharia, MD.
Experts will discuss advancements in prostate, kidney, bladder cancers and more. โก๏ธ brnw.ch/21wQYd6
Rohan Garje, MD, FASCO retweeted
๐งฌ Liquid Biopsy in Clinical Practice: Past, Present & Future๐ฉธ
A new review explores the evolution, applications, and future directions of liquid biopsy in oncology. Here are the key insights:
๐ฌTechnologies & Biomarkers
โ
Circulating Tumor Cells (CTCs) โ Enrichment & detection methods (PCR, IHC, FISH, scRNA-seq)
โ
Circulating Tumor DNA (ctDNA) โ PCR & NGS-based detection for genomic alterations
โ
Exosomes โ Advanced methods for isolating tumor-derived extracellular vesicles
๐Clinical Applications
โ
Early Cancer Detectionโ Liquid biopsy enhances non-invasive screening
โ
Cancer Staging & Prognosisโ Stratifies patients based on risk & molecular profiling
โ
Therapy Guidance โ Detects actionable mutations like ESR1, PIK3CA, EGFR, ALK for precision medicine
โ
Treatment Response Monitoring โ Tracks minimal residual disease (MRD) & therapy resistance
๐Advancing Liquid Biopsy for Multi-Cancer Screening
โ
Emerging multi-cancer detection technologies: CCGA3, CancerSEEK, THUNDER, DETECT-A, PATHFINDER
โ
AI & machine learning integration for enhanced diagnostic accuracy
๐ฎFuture Directions
โ
Standardization & Validation โ Steps to clinical utility
โ
Multi-Omics Approach โ Integrating genomics, transcriptomics, and proteomics
โ
Ex Vivo Models โ Using CDX mouse models for precision therapy testing
๐Liquid biopsy is revolutionizing oncologyโenhancing early detection, personalized treatment & real-time monitoring.
๐ Read the full study: doi.org/10.1016/j.critrevoncโฆ
@DrYukselUrun @ChristianRolfo @ElJanLe @UmbertoMalapel1 @oncodaily @ErulEnes @drgandara @MJOSESERRANO19 @CHematology @Elsevier_Med
#LiquidBiopsy #PrecisionOncology #ctDNA #CancerDetection #ISLB ๐
